Jiangsu Recbio Technology Co., Ltd. (2179.HK)
HKD 8.0
(2.56%)
HKD 8.0
(2.56%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -569.86 Million CNY | 18.01% |
| 2022 | -847.66 Million CNY | -17.8% |
| 2021 | -589.99 Million CNY | -337.34% |
| 2020 | -134.9 Million CNY | -97.15% |
| 2019 | -68.42 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -108.83 Million CNY | 0.0% |
| 2024 Q1 | -108.83 Million CNY | 17.74% |
| 2023 Q4 | -132.29 Million CNY | 0.0% |
| 2023 FY | - CNY | 18.01% |
| 2023 Q2 | -152.63 Million CNY | 0.0% |
| 2023 Q3 | -132.29 Million CNY | 13.33% |
| 2023 Q1 | -152.63 Million CNY | 28.61% |
| 2022 Q2 | -210.01 Million CNY | 0.0% |
| 2022 Q1 | -210.01 Million CNY | -59.19% |
| 2022 FY | - CNY | -17.8% |
| 2022 Q4 | -213.82 Million CNY | 0.0% |
| 2022 Q3 | -213.82 Million CNY | -1.81% |
| 2021 FY | - CNY | -337.34% |
| 2021 Q3 | -188.53 Million CNY | -35.09% |
| 2021 Q2 | -139.56 Million CNY | 0.0% |
| 2021 Q1 | -139.56 Million CNY | -70.37% |
| 2021 Q4 | -131.92 Million CNY | 30.03% |
| 2020 Q4 | -81.91 Million CNY | 0.0% |
| 2020 FY | - CNY | -97.15% |
| 2019 FY | - CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 91.23 Million HKD | 724.623% |
| CK Life Sciences Int'l., (Holdings) Inc. | 486.79 Million HKD | 217.065% |